2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.083 Matthew Lee

PP01.083 Matthew Lee_NACLC23 Abstract

Pdf Summary

The VISION study explored the treatment sequencing of tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). The study included 313 patients, with 164 in the first-line (1L) and 149 in the second-line (2L) settings. Prior to enrolling in the study, the most common first-line regimen among 2L patients was platinum-based chemotherapy without immunotherapy (IO), followed by IO monotherapy and IO-chemotherapy. The median duration of treatment for all prior first-line regimens was 4 months, with an objective response rate (ORR) of 24.8%, median duration of response (mDOR) of 6.0 months, and median progression-free survival (mPFS) of 4.0 months. In contrast, the outcomes with tepotinib in the first-line setting were significantly improved.<br /><br />Overall, 84.7% of patients discontinued tepotinib, with 46.8% of them receiving subsequent treatment. Among those who received subsequent treatment, 48 patients received MET inhibitors (METi), with 31 receiving METi immediately after tepotinib. The best overall response with subsequent METi was three partial responses (PR) and 11 stable disease (SD), with a median duration of response (mDOR) of 4.0 months and median progression-free survival (mPFS) of 2.5 months. The outcomes with subsequent chemotherapy/immunotherapy (CT/IO) were comparable to prior CT/IO regimens and literature reports.<br /><br />The study concludes that tepotinib demonstrated robust and durable efficacy, particularly in the first-line setting, supporting its early use in the treatment sequence. Additionally, almost half of the elderly population in the study received subsequent treatment, which was higher than reported rates in similar studies. The findings suggest that tepotinib may be a valuable treatment option for patients with METex14 skipping NSCLC. The study was sponsored by the healthcare business of Merck KGaA and received medical writing support funded by Merck KGaA.

Keywords

VISION study

tepotinib

MET exon 14 skipping

non-small cell lung cancer

NSCLC

treatment sequencing

first-line setting

second-line setting

chemotherapy

immunotherapy